Xifamin 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Nipro jmi pharma ltd |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase and exerts bactericidal action against many species of bacteria.
Dosage & Administration
- For traveler's diarrhea: 200 mg 3 times daily for 3 days (patients ≥12 years of age)
- For hepatic encephalopathy: 550 mg 2 times daily (patients ≥18 years of age)
- For bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Can be taken with or without food
Interaction
In vitro study has suggested that Xifamin induces CYP3A4. However, in patients with normal liver function, Xifamin at the recommended dosing regimen is not expected to induce CYP3A4.
Contraindications
Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. It is not known whether Rifaximin is excreted in human milk.
Precautions & Warnings
- Xifamin is not effective in patients with diarrhea complicated by fever and/or blood in the stools
- Xifamin therapy should be discontinued if diarrhea symptoms worsen or persist for more than 24-48 hours
- Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening
Use in Special Populations
- Renal Impairment: The pharmacokinetics of Xifamin in patients with impaired renal function has not been studied
- Hepatic Impairment: The systemic exposure of Xifamin was markedly elevated in patients with hepatic impairment compared to healthy subjects
Overdose Effects
No specific information is available on the treatment of overdose with Xifamin.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.